Abstract
Many overweight or obese people struggle to sustain the behavioural changes necessary to achieve and maintain weight loss. In rodents, obesogenic diet can disrupt goal-directed control of responding for food reinforcers, which may indicate that diet can disrupt brain regions associated with behavioural control. We investigated a potential glutamatergic mechanism to return goal-directed control to rats who had been given an obesogenic diet prior to operant training. We found that an obesogenic diet reduced goal-directed control and that systemic injection of LY379268, a Group II metabotropic glutamate receptor (mGluR2/3) agonist, returned goal-directed responding in these rats. Further, we found that direct infusion of LY379268 into the dorsomedial striatum, a region associated with goal-directed control, also restored goal-directed responding in the obesogenic-diet group. This indicates that one mechanism through which obesogenic diet disrupts goal-directed control is glutamatergic, and infusion of a mGluR2/3 agonist into the DMS is sufficient to ameliorate deficits in goal-directed control.
Highlights
Obesity, and associated disease burden, is a preventable global health problem with over half of the adult population being classified as overweight or obese in 2016, equating to 1.9 billion people worldwide [1]
Furlong et al [4] showed that feeding rats a diet of sweetened condensed milk (SCM) for five weeks prior to instrumental training, where rats learned to press a lever for a different food reinforcer, resulted in insensitivity to the devaluation of that outcome following an amount of training where control subjects were sensitive to devaluation
Across days and that the SCM groups responded less than chow and to test our hypothesis that LY379268 would rescue a dietinduced impairment, we examined the effect of LY379268 on sensitivity to devaluation in each the Chow and SCM groups
Summary
Associated disease burden, is a preventable global health problem with over half of the adult population being classified as overweight or obese in 2016, equating to 1.9 billion people worldwide [1]. These analyses and results from Experiment 1 suggest that overall, there and importantly, treatment with LY379268 improved sensitivity to is not a consistent sex difference or effect of diet on instrumental devaluation evidenced by a drug x devaluation interaction responding by the end of acquisition.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.